Market Overview

UPDATE: Barclays Raises PT to $57 on CVS Caremark Following Meeting with Management

Share:
Related CVS
CVS Health Q1'16 Earnings Conference Call: Full Transcript
CVS Rallies After Q1 Report
Why Amazon's World Domination May Come Sooner Than You Think (Investor's Business Daily)

Barclays reiterated its Overweight rating on CVS Caremark (NYSE: CVS) and raised its price target from $54 to $57.

Barclays noted, "At CVS Caremark's 2012 analyst meeting, management showed investors how the company's business model gives it meaningful competitive advantages as the US healthcare industry is transformed. [P]erhaps most significant, is the change in rationale for payments to healthcare providers, especially doctors and hospitals, as the nation moves from fee-for-service to outcomes-based payment. We see many approaches to pay-for-performance, but encouraging patients to remain adherent to their medications is crucial to all of them."

CVS Caremark closed at $49.24 on Friday.

Latest Ratings for CVS

DateFirmActionFromTo
Mar 2016Credit SuisseAssumesOutperform
Mar 2016BarclaysAssumesOverweight
Feb 2016Atlantic EquitiesInitiates Coverage onOverweight

View More Analyst Ratings for CVS
View the Latest Analyst Ratings

Posted-In: BarclaysAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (CVS)

View Comments and Join the Discussion!